GE HealthCare Technologies Inc. (NASDAQ:GEHC) is one of the best NASDAQ stocks with the highest upside potential.
Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...
BERLIN--(BUSINESS WIRE)--Bayer, a global leader in radiology, today announced positive topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an ...
Mangaciclanol’s Phase I trial showed it was well tolerated, with no serious adverse events or clinically significant findings.
Mangaciclanol, if approved, could transform contrast-enhanced MR imaging by offering an alternative to - or even replacing - gadolinium-based MRI agents A manganese-based MRI contrast agent could ...
Contrast-enhanced in-phase Dixon sequence could reduce the need for correlation among other imaging modalities to better identify areas of prior biopsy during breast MRI interpretation, according to a ...
Hosted on MSN
What to know about MRI contrast safety
MRI contrast agents, especially gadolinium-based ones, can improve diagnostic accuracy but also carry potential health risks. Updated clinical recommendations emphasize careful patient selection, dose ...
MRI contrast agents, which are typically gadolinium-based, are used to enhance visualization of abnormal structures or lesions and to aid differentiation between healthy and pathological tissue. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results